Palliative Care – Cannabis Research

Palliative Care Research Dashboard

30

Primary Studies

8

Related Studies

38

Total Studies

Clinical Studies

1

Clinical Meta-analyses

0

Double-blind human trials

3

Clinical human trials

Pre-Clinical Studies

26

Meta-analyses/Reviews

0

Animal studies

0

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 38 studies associated with Palliative Care.

Here is a small sampling of Palliative Care studies by title:


Components of the Palliative Care Research Dashboard

  • Dosing information available for Palliative Care
  • Chemotype guidance for treating Palliative Care with cannabis
  • Synopsis of cannabis research for Palliative Care
  • Individual study details for Palliative Care

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Palliative Care

Description of Palliative Care

Hospice care is focused on the quality of life of patients in their last stage of life where death is expected and near (two physicians have certified that patient has less than 6 month to live). The key idea here is to make their last months or days as comfortable as possible. However, many end-of-life patients are challenged by the limitations of available orthodox treatment options. For instance, in some cases patients have developed a tolerance that even the strongest analgesics (e.g. opioids) do not work anymore at non-fatal dosages. Or, they may still produce pain relief but the nausea, vomiting, constipation, and other adverse effects are so severe that patients simply opt out and choose pain over the adverse effects leaving them between a rock and a hard place. Palliative care similarly shares the goal of hospice in minimizing physical and mental-emotional symptoms and distress. However, the scope of palliative care includes also caring for patients with chronic and serious illnesses and not just end-of-life care. There are a number of patient setting that can use a palliative approach including the family or patients home, convalescent or rest-homes, hospitals, clinics, and of course hospice settings. Patient populations that commonly benefit from palliative care include those with chronic degenerative conditions such as Alzheimer’s disease, MS, Parkinson’s disease, Huntington’s disease, cancer care, congestive heart failure, or emphysema for example.

Disease Classification

Condition: Palliative Care
Disease Family:
Organ System: Cardiovascular System, Digestive System, Endocrine System, Immune System, Integumentary System, Mental/Emotional System, Muscular System, Nervous System, Reproductive System, Respiratory System, Skeletal System, Urinary System
ICD-10 Chapter: Encounter for Other Aftercare and Medical Care
ICD-10 Code: Z51.5

Palliative Care Symptoms:

Hard to manage pain, emotional distress, depression, anxiety

Also known as:

Hospice Care, End of Life Care, Comfort care only status

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • Tetrahydrocannabinol (THC) can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol. 
  • THC is metabolized by an inhibitor of several enzymatic liver pathways referred to as cytochrome P450 (aka CYP450). There are more than 50 enzymes belonging to this enzyme family, several of which are responsible for the breakdown of common drugs such as antidepressants (e.g., amitriptyline, doxepin, fluvoxamine), antipsychotics (haloperidol, clozapine, Stelazine), beta-blockers (e.g., propranolol), bronchodilators (e.g., theophylline), or blood thinners (e.g., warfarin). Thus, patients taking these medication classes may find that THC increases the concentration and effects of these drugs and the impact duration.
  • Clinical observation (not yet confirmed by clinical trials) suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

If you are interested in the interaction potential of specific pharmaceuticals with THC, consider visiting CANN-DIR, published by Penn State College of Medicine.

CBD Interaction with Pharmaceutical Drugs

  • Cannabidiol (CBD) may alter the action of metabolic enzymes (specific drug-transport mechanisms) and alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include anti-epileptics, psychiatric drugs, and drugs affecting metabolic enzymes.
  • Clinical observations (not yet confirmed by clinical trials) suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD.

If you are interested in the interaction potential of specific pharmaceuticals with CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.

THC/CBD Interaction with Pharmaceutical Drugs

In general, when using cannabinoid-based therapeutics that contain both THC and CBD consider the ratio between them and weigh the relevant information displayed in the individual THC and CBD Drug Interaction windows accordingly.

If you are interested in the interaction potential of specific pharmaceuticals with both primary cannabinoids and THC/CBD, consider visiting CANN-DIR, published by Penn State College of Medicine.

Concerns about Cannabis and Cancer-related Immunotherapies:
Some recent clinical observational studies have suggested that the co-administration of cannabinoid-based therapeutics and immunotherapy or immune checkpoint inhibitors in the treatment of certain types of cancer has been associated with worse overall survival rates (T. Taha et al., 2019; A. Biedny et al., 2020; G. Bar-Sela et al., 2020).

However, other studies have suggested that the co-commitment use of immune checkpoint inhibitors and cannabis-induced no such deleterious effects. More specifically, one trial was conducted on animals resulting in data suggesting that cannabis did not negatively affect the properties of immune checkpoint inhibitors (B. Waissengrin et al., 2023). The same authors compared the previous study results with findings from a cohort of 201 patients with metastatic non-small cell lung cancer who received treatment with monotherapy pembrolizumab as a first-line treatment and adjunct cannabis to treat mainly pain and loss of appetite. Their time to tumor progression was 6.1 versus 5.6 months, and overall survival differed between 54.9 versus 23.6 months in cannabis-naïve patients and cannabis-using patients, respectively. However, while numerically different, the authors write that these differences were not statistically significant, leading them to suggest that “These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.”

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg
  • THC low dose:  0.5 mg to 5 mg
  • THC medium dose:  6 mg to 20 mg
  • THC high dose:  21 mg to 50+ mg

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg
  • CBD medium dose: 20 mg to 99 mg
  • CBD high dose:  100 mg to 800+ mg (upper limits tested ~1,500mg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.